The Change in HbA1c Associated with Initial Adherence and Subsequent Change in Adherence among Diabetes Patients Newly Initiating Metformin Therapy

Gregory A Nichols, A Gabriela Rosales, Teresa M Kimes, Kaan Tunceli, Karen Kurtyka, Panagiotis Mavros, Gregory A Nichols, A Gabriela Rosales, Teresa M Kimes, Kaan Tunceli, Karen Kurtyka, Panagiotis Mavros

Abstract

Introduction. Whether changes in adherence are associated with changes in HbA1c is assumed but not known. Methods. We conducted a observational study of 2,844 type 2 diabetes patients who initiated metformin as their first antihyperglycemic drug. Using HbA1c measures before, 6-12 months after, and up to 3 years after metformin initiation, we analyzed HbA1c change as a function of initial adherence and change in adherence. Results. Compared with no adherence, initial adherence of 50-79% was associated with an adjusted reduction in HbA1c of 0.45% while adherence ≥80% was associated with HbA1c reduction of 0.73%. Change from some initial adherence (1-79%) to total nonadherence was associated with 0.25% increase in HbA1c. Change from some to full adherence was associated with an HbA1c decrease of 0.15%. Those associations were accentuated among patients not in glycemic control: change from some to no adherence was associated with an HbA1c increase of 0.63% and change from some to full adherence was associated with an HbA1c decrease of 0.40%. Conclusions. Initial adherence to newly prescribed metformin therapy produces substantial HbA1c reduction. Among those with modest adherence but suboptimal glycemic control, the difference between moving to full adherence versus nonadherence results in lower HbA1c of one percentage point.

Figures

Figure 1
Figure 1
Percentage point change in HbA1c before and 6–12 months after metformin initiation by category of Biologic Response Based Proportion of Days Covered where 0% is the reference group (Analysis 1). Error bars represent 95% confidence intervals.
Figure 2
Figure 2
Percentage point change in HbA1c between first HbA1c measured 6–12 months after metformin initiation and last HbA1c of observation period measured 3–21 months later by change in category of Biologic Response Based Proportion of Days Covered where no change is the reference group. Data are for the total sample (Analysis 2). Error bars represent 95% confidence intervals.
Figure 3
Figure 3
Percentage point change in HbA1c between first HbA1c measured 6–12 months after metformin initiation and last HbA1c of observation period measured 3–21 months later by change in category of Biologic Response Based Proportion of Days Covered where no change is the reference group. Data are for those whose HbA1c measured 6–12 months after metformin initiation was ≥7% (Analysis 3). Error bars represent 95% confidence intervals.

References

    1. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38:S1–S87.
    1. Nichols G. A., Conner C., Brown J. B. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. Current Medical Research and Opinion. 2010;26(9):2127–2135. doi: 10.1185/03007995.2010.504396.
    1. Brown J. B., Conner C., Nichols G. A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501–506. doi: 10.2337/dc09-1749.
    1. Asche C., LaFleur J., Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clinical Therapeutics. 2011;33(1):74–109. doi: 10.1016/j.clinthera.2011.01.019.
    1. Raebel M. A., Schmittdiel J., Karter A. J., Konieczny J. L., Steiner J. F. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Medical Care. 2013;51(8):S11–S21. doi: 10.1097/MLR.0b013e31829b1d2a.
    1. Nichols G. A., Rosales A. G., Kimes T. M., et al. Impact on glycated haemoglobin of a biological response-based measure of medication adherence. Diabetes, Obesity and Metabolism. 2015;17(9):843–848. doi: 10.1111/dom.12476.
    1. Nichols G. A., Koo Y. H., Shah S. N. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. Journal of General Internal Medicine. 2007;22(4):453–458. doi: 10.1007/s11606-007-0139-y.
    1. Steiner J. F. Rethinking adherence. Annals of Internal Medicine. 2012;157(8):580–585. doi: 10.7326/0003-4819-157-8-201210160-00013.
    1. Feldstein A. C., Perrin N. A., Unitan R., et al. Effect of a patient panel-support tool on care delivery. American Journal of Managed Care. 2010;16(10):e256–e266.
    1. Inzucchi S. E., Bergenstal R. M., Buse J. B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35(6):1364–1379. doi: 10.2337/dc12-0413.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera